Aratana Therapeutics Inc (fka PETX)

[biotech_researcher]

So, PETX received $5.4-$2.2 or $3.2 million of actual product revenue from Galliprant in Q3 2017, so on March 14th, we will have another data point on Galli’s organic growth rate. It should at least double, I hope..................

Aratana recorded $5.4 million in revenues during the third quarter of 2017 related to GALLIPRANT® (grapiprant tablets), including $2.2 million in GALLIPRANT licensing and collaboration revenue from Elanco Animal Health, a division of Eli Lilly and Company. Third quarter 2017 GALLIPRANT licensing and collaboration revenue included a $1.0 million one-time payment for the transfer of manufacturing responsibility to Elanco. The remaining $1.2 million of GALLIPRANT licensing and collaboration revenue compares to $0.8 million in the second quarter of 2017.